Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 131.36B |
| Revenue (ttm) | 23.16B |
| Net Income (ttm) | 8.71B |
| Shares Out | 61.55M |
| EPS (ttm) | 137.33 |
| PE Ratio | 15.54 |
| Forward PE | 20.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 202,036 |
| Average Volume | 176,984 |
| Open | 2,077.00 |
| Previous Close | 2,134.00 |
| Day's Range | 2,051.00 - 2,120.00 |
| 52-Week Range | 1,157.00 - 2,153.00 |
| Beta | 0.82 |
| RSI | 68.52 |
| Earnings Date | Nov 6, 2025 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial numbers in USD Financial StatementsNews
Genmab (GMAB) Analyst Reiterates Buy Rating and Maintains $40 Target | GMAB Stock News
Genmab (GMAB) Analyst Reiterates Buy Rating and Maintains $40 Target | GMAB Stock News
Genmab (GMAB) Reports Strong Q3 2025 Sales for Darzalex
Genmab (GMAB) Reports Strong Q3 2025 Sales for Darzalex
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
Company Announcement Net sales of DARZALEX ® in the third quarter of 2025 totaled USD 3,672 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Genmab (GMAB) Stock Rises on Positive Analyst Updates
Genmab (GMAB) Stock Rises on Positive Analyst Updates
Why Genmab Stock Popped on Friday
Two pundits raised their price targets on the company.
Best Momentum Stock to Buy for October 3rd
GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.
New Strong Buy Stocks for October 3rd
DORM, AEG, GMAB, SCSC and GFI have been added to the Zacks Rank #1 (Strong Buy) List on October 3rd, 2025.
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...
Genmab (GMAB) Stock Rises After Acquisition Announcement
Genmab (GMAB) Stock Rises After Acquisition Announcement
Why Genmab Stock Was Marching Higher Today
The company's latest asset purchase seems to be impressing analysts.
Genmab A/S (GMAB) M&A Call Transcript
Genmab A/S (GMAB) M&A Call September 29, 2025 7:00 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimen...
Genmab to Acquire Merus in $8 Billion All-Cash Deal
Genmab to Acquire Merus in $8 Billion All-Cash Deal
Genmab Makes A Big Bet With Merus N.V. Acquisition
Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue
Genmab acquires Merus for $8bn, adding promising oncology asset petosemtamab. Check out my thoughts on this deal and my ratings on GMAB and MRUS stocks.
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...
Merus (MRUS) Surges 38% Following Genmab Acquisition Announcement
Merus (MRUS) Surges 38% Following Genmab Acquisition Announcement
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
Genmab, on Monday, announced its plan to buy Merus for about $8 billion. The news sent Merus stock into the stratosphere.
First Look: Genmab Eyes Merus Acquisition Amid BP's $5B Project Approval
First Look: Genmab Eyes Merus Acquisition Amid BP's $5B Project Approval
This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.
Genmab will acquire Merus in an all-cash transaction worth around $8 billion.
Genmab (GMAB) Plans to Acquire Merus in $8 Billion Deal
Genmab (GMAB) Plans to Acquire Merus in $8 Billion Deal
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading . Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its ...
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline
Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...
Genmab to Buy Cancer-Treatment Developer Merus For $8 Billion in Cash
Genmab To Acquire Merus In $8 Bln Cash Deal
(RTTNews) - Denmark's Genmab A/S (GMAB) has agreed to acquire Merus NV (MRUS), a Dutch biopharmaceutical company focused on treatments for head and neck cancer, in an all-cash transaction valued at ap...
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.